Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
---|---|---|---|---|---|
08.08. | Y-mAbs Therapeutics, Inc. - 10-Q, Quarterly Report | 1 | SEC Filings | ||
Y-MABS THERAPEUTICS Aktie jetzt für 0€ handeln | |||||
08.08. | Y-mAbs Therapeutics GAAP EPS of -$0.07 beats by $0.19, revenue of $19.53M beats by $1.13M | 1 | Seeking Alpha | ||
08.08. | Y-mAbs Therapeutics, Inc.: Y-mAbs Reports Second Quarter 2025 Financial Results and Recent Corporate Developments | 183 | GlobeNewswire (Europe) | Reported Total Revenues of $19.5 million for the second quarter of 2025, exceeding the high end of the Company's guidance range of between $17 million and $19 millionSERB Pharmaceuticals to acquire... ► Artikel lesen | |
07.08. | A Look Ahead: Y-mAbs Therapeutics' Earnings Forecast | 1 | Benzinga.com | ||
07.08. | Y-mAbs Therapeutics, Inc.: Y-mAbs to Announce Second Quarter 2025 Financial and Operating Results on August 8, 2025 | 2 | GlobeNewswire (USA) | ||
05.08. | Y-mAbs Therapeutics stock downgraded to Hold by Truist after SERB acquisition | 2 | Investing.com | ||
05.08. | Y-mAbs stock soars after SERB Pharmaceuticals announces acquisition | 2 | Investing.com | ||
05.08. | Y-mAbs signs off on $412M sale to SERB Pharmaceuticals, sending shares up 100% | 1 | FiercePharma | ||
05.08. | SERB To Acquire Y-mAbs | 2 | RTTNews | ||
05.08. | Y-mAbs Therapeutics, Inc. - 8-K, Current Report | 1 | SEC Filings | ||
05.08. | SERB Pharmaceuticals to acquire Y-mAbs Therapeutics for $412M | 1 | Seeking Alpha | ||
15.07. | Y-mAbs Therapeutics: Aktionäre stimmen auf Hauptversammlung allen Vorschlägen zu | 2 | Investing.com Deutsch | ||
15.07. | Y-mAbs Therapeutics, Inc. - 8-K, Current Report | 2 | SEC Filings | ||
28.05. | Clear Street erhöht Kursziel für YMAB-Aktie auf 17 US-Dollar, Aktien steigen | 1 | Investing.com Deutsch | ||
28.05. | Clear Street raises YMAB stock target to $17, shares rise | 1 | Investing.com | ||
28.05. | Y-mAbs Therapeutics, Inc. - 8-K, Current Report | 1 | SEC Filings | ||
28.05. | Y-mAbs Therapeutics, Inc.: Y-mAbs Hosts Virtual Radiopharmaceutical R&D Update Highlighting Clinical Progress and Expanded Pipeline | 3 | GlobeNewswire (USA) | ||
26.05. | Y-mAbs Therapeutics, Inc.: Y-mAbs Presents GD2-SADA PRIT Trial in Progress Poster at the Advances in Neuroblastoma Research Meeting | 2 | GlobeNewswire (USA) | ||
19.05. | What 7 Analyst Ratings Have To Say About Y-mAbs Therapeutics | 1 | Benzinga.com | ||
19.05. | H.C. Wainwright cuts YMAB stock target to $11, maintains Buy rating | 1 | Investing.com |
Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
---|---|---|---|---|---|
BIONTECH | 85,65 | +0,06 % | Paukenschlag beim Übernahmekandidaten! 100 %-Aktie BioNxt Solutions lässt BioNTech und Co. hinter sich! | Die Aktie von BioNxt ist endlich angesprungen. Anfang Juli hatten wir zuletzt auf die Chancen des kanadisch-deutschen Biowissenschaftsunternehmens hingewiesen. Seitdem ist die Aktie um fast 100 % gestiegen... ► Artikel lesen | |
EVOTEC | 6,000 | +0,03 % | Die Blaupause für KI-Medikamentenentwicklung: So nutzen Evotec, NetraMark Holdings und BioNTech die neuen Möglichkeiten | Die Pharmabranche befindet sich mitten in einer Revolution. Künstliche Intelligenz verkürzt die Wirkstoffentwicklung von Jahren auf Monate und steigert die Trefferquote dramatisch. Datengetriebene Prognosen... ► Artikel lesen | |
CUREVAC | 4,618 | +0,70 % | CureVac mit EILMELDUNG: Könnte die Aktie am Montag komplett einbrechen - Experten warnen!!! | ||
MODERNA | 20,610 | +0,12 % | Moderna, Inc.: Moderna Receives U.S. FDA Approval for Updated COVID-19 Vaccines Targeting LP.8.1 Variant of SARS-CoV-2 | CAMBRIDGE, MA / ACCESS Newswire / August 27, 2025 / Moderna, Inc. (NASDAQ:MRNA) today announced that the U.S. Food and Drug Administration (FDA) has approved the supplemental Biologics License Applications... ► Artikel lesen | |
NOVAVAX | 6,377 | -0,20 % | H.C. Wainwright startet Coverage für Novavax mit "Buy"-Rating und Kursziel von 10 US-Dollar | ||
HEIDELBERG PHARMA | 3,610 | -1,90 % | EQS-Adhoc: Heidelberg Pharma AG: Heidelberg Pharmas Partner Telix Pharmaceuticals informiert über Stand des Zulassungsantrags für sein Diagnostikum TLX250-CDx | EQS-Ad-hoc: Heidelberg Pharma AG / Schlagwort(e): Finanzierung
Heidelberg Pharmas Partner Telix Pharmaceuticals informiert über Stand des Zulassungsantrags für sein Diagnostikum TLX250-CDx... ► Artikel lesen | |
CRISPR THERAPEUTICS | 44,200 | -0,45 % | 1 Reason Every Investor Should Know About CRISPR Therapeutics (CRSP) | ||
INOVIO PHARMACEUTICALS | 1,980 | -1,98 % | INO Stock Soars as FDA Backs Rolling BLA for Rare Lung Disease Drug | ||
INTELLIA THERAPEUTICS | 9,760 | +0,56 % | ARK Invest: Cathie Wood setzt auf Biotech-Wert Intellia und reduziert DraftKings-Position | ||
SCORPIUS | 0,072 | 0,00 % | Scorpius Holdings, Inc.: Scorpius Holdings Announces Corporate Update Including Cost Optimization Initiatives, Strategic Corporate Developments, and Potential Opportunities for Expansion into Southeast Asia | Operational Realignment Expected to Deliver Over $6 Million in Annual Cost Savings Company Exploring CDMO Expansion Opportunities in Southeast Asia San Antonio, TX, May 04, 2025 (GLOBE NEWSWIRE)... ► Artikel lesen | |
EDITAS MEDICINE | 2,149 | -2,01 % | Editas Medicine, Inc.: Editas Medicine Announces Second Quarter 2025 Results and Business Updates | Company to select lead development candidate in September; on track to file IND by mid-2026 and achieve human proof-of-concept by year-end 2026 First IND/CTA accepted for CD19 HD Allo CAR T program... ► Artikel lesen | |
TREVENA | 2,280 | -40,00 % | Hollywood Changemaker Oliver Trevena Joins Little Kitchen Academy as Investor | LOS ANGELES, CA / ACCESS Newswire / August 21, 2025 / Little Kitchen Academy (LKA), the premier Montessori-inspired cooking academy for children and teens ages 3-18, is proud to announce that Oliver... ► Artikel lesen | |
DYNAVAX | 9,048 | +4,65 % | Dynavax Technologies: Dynavax Announces Positive Topline Phase 1/2 Results Supporting Potential Best-in-Class Shingles Vaccine Profile | At all doses and formulations evaluated in Part 1 of the trial, Z-1018 was well-tolerated and demonstrated a favorable tolerability profile, including lower solicited... ► Artikel lesen | |
SAREPTA THERAPEUTICS | 15,510 | -0,42 % | S&P Dow Jones Indices: Elanco Animal Health Set to Join S&P MidCap 400; Sarepta Therapeutics to Join S&P SmallCap 600 | NEW YORK, Aug. 26, 2025 /PRNewswire/ -- Elanco Animal Health Inc. (NYSE: ELAN) will replace Sarepta Therapeutics Inc. (NASD: SRPT) in the S&P MidCap 400, and... ► Artikel lesen | |
BIOMARIN PHARMACEUTICAL | 49,940 | +0,24 % | Sanofi snags BioMarin leader to take on CMO role 8 months after Berger's exit |